APS Biogroup Warned On Parent Firm’s Children’s DiaResQ Misbranding
This article was originally published in The Rose Sheet
Executive Summary
An FDA warning letter says during an inspection at Phoenix firm APS Biogroup’s facility in February, ORA Denver district officials found violative claims in addition to branding problems.